Aldeyra Therapeutics (ALDX) Stock Overview
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ALDX Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Aldeyra Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.96 |
| 52 Week High | US$6.18 |
| 52 Week Low | US$1.07 |
| Beta | 1.19 |
| 1 Month Change | 27.27% |
| 3 Month Change | 8.29% |
| 1 Year Change | -38.17% |
| 3 Year Change | -74.71% |
| 5 Year Change | -82.58% |
| Change since IPO | -72.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.6% | 1.3% | 1.7% |
| 1Y | -38.2% | 31.1% | 25.1% |
Return vs Industry: ALDX underperformed the US Biotechs industry which returned 30.5% over the past year.
Return vs Market: ALDX underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| ALDX volatility | |
|---|---|
| ALDX Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALDX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALDX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 7 | Todd Brady | www.aldeyra.com |
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication.
Aldeyra Therapeutics, Inc. Fundamentals Summary
| ALDX fundamental statistics | |
|---|---|
| Market cap | US$110.39m |
| Earnings (TTM) | -US$27.37m |
| Revenue (TTM) | n/a |
Is ALDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALDX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$27.37m |
| Earnings | -US$27.37m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 36.3% |
How did ALDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/18 00:11 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aldeyra Therapeutics, Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Esther Lannie Hong | Berenberg |
| Douglas Buchanan | Brean Capital Historical (Janney Montgomery) |